RU2393872C2 - Лечение вич инфекции посредством т-клеточной модуляции - Google Patents

Лечение вич инфекции посредством т-клеточной модуляции Download PDF

Info

Publication number
RU2393872C2
RU2393872C2 RU2007111566/14A RU2007111566A RU2393872C2 RU 2393872 C2 RU2393872 C2 RU 2393872C2 RU 2007111566/14 A RU2007111566/14 A RU 2007111566/14A RU 2007111566 A RU2007111566 A RU 2007111566A RU 2393872 C2 RU2393872 C2 RU 2393872C2
Authority
RU
Russia
Prior art keywords
hiv
cells
cell
treatment
immune system
Prior art date
Application number
RU2007111566/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2007111566A (ru
Inventor
Вернер КРАУЗЕ (DE)
Вернер КРАУЗЕ
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of RU2007111566A publication Critical patent/RU2007111566A/ru
Application granted granted Critical
Publication of RU2393872C2 publication Critical patent/RU2393872C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2007111566/14A 2004-08-30 2005-07-28 Лечение вич инфекции посредством т-клеточной модуляции RU2393872C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60517304P 2004-08-30 2004-08-30
US60/605,173 2004-08-30

Publications (2)

Publication Number Publication Date
RU2007111566A RU2007111566A (ru) 2008-10-10
RU2393872C2 true RU2393872C2 (ru) 2010-07-10

Family

ID=35079284

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007111566/14A RU2393872C2 (ru) 2004-08-30 2005-07-28 Лечение вич инфекции посредством т-клеточной модуляции

Country Status (14)

Country Link
US (1) US20060057620A1 (https=)
EP (1) EP1784217A1 (https=)
JP (1) JP2008511559A (https=)
KR (1) KR20070050934A (https=)
AU (1) AU2005279460A1 (https=)
BR (1) BRPI0514729A (https=)
CA (1) CA2570735A1 (https=)
IL (1) IL179856A (https=)
MX (1) MX2007002188A (https=)
NO (1) NO20071700L (https=)
RU (1) RU2393872C2 (https=)
TW (1) TW200626172A (https=)
WO (1) WO2006024354A1 (https=)
ZA (1) ZA200702654B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008829A1 (en) * 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FOX C.H. et al., OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+Т cell depletion, J Clin Immunol. 2001 May, 21 (3), p.218-226, реферат. *
ПТУШКИН В.В. Роль гранулоцитарного и гранулоцитарно-макрофагального колониестимулирующих факторов в лечении инфекции при нейтропении. - Современная онкология, том 3, №3, 2001, [он-лайн] [Найдено 2009.04.20] найдено из Интернет: http://www.consilium-medicum.com/magazines/special/cancer/article/8395. FRACER С et al., Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS. 2000 Apr 14. 14(6), p.659-669, реферат. *

Also Published As

Publication number Publication date
KR20070050934A (ko) 2007-05-16
US20060057620A1 (en) 2006-03-16
WO2006024354A1 (en) 2006-03-09
ZA200702654B (en) 2008-08-27
CA2570735A1 (en) 2006-03-09
AU2005279460A1 (en) 2006-03-09
NO20071700L (no) 2007-05-29
IL179856A0 (en) 2007-05-15
EP1784217A1 (en) 2007-05-16
TW200626172A (en) 2006-08-01
JP2008511559A (ja) 2008-04-17
BRPI0514729A (pt) 2008-06-24
IL179856A (en) 2010-11-30
MX2007002188A (es) 2007-10-16
RU2007111566A (ru) 2008-10-10

Similar Documents

Publication Publication Date Title
US20020147130A1 (en) Treatment of hiv
JP2018135370A (ja) 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
Imafuku et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open‐label, phase 3 trial
Gudbrandsdottir et al. Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children.
JPH11139977A (ja) Ｎｅｆ作用抑制剤
JP2022514561A5 (https=)
RU2393872C2 (ru) Лечение вич инфекции посредством т-клеточной модуляции
US11376268B2 (en) Methods and materials for treating human immunodeficiency virus infections
US10336817B2 (en) Therapeutic composition of camel milk
HUT56855A (en) Process for producing antiviral pharmaceutical compositions
JPH02117622A (ja) 免疫抑制を行なう方法
US20060121480A1 (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
US6251874B1 (en) Method of inhibiting human immunodeficiency virus using hydroxurea and a reverse transcriptase inhibitor in vivo
WO2023070058A1 (en) Treatment of viruses with antiviral nucleosides
Hassan A Global Update on COVID-19 Pandemic: A Global Update on COVID-19 Pandemic
US20080233128A1 (en) Treatment of Viral Infections
RU2261105C1 (ru) Способ профилактики клещевого энцефалита
US20250205268A1 (en) Treatment of viruses with antiviral nucleosides
Cainelli et al. Lymph nodes and pathogenesis of infection with HIV-1
Becker A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity–hypothesis and implications
Bekerman et al. The Use of Nonhuman Primate Models for Advancing HIV PrEP
Kawade et al. AIDS THERAPY: INFLUENCE ON NEW DRUGS
CN102727523A (zh) 一种具有抗hiv潜伏作用的药物及其用途
Hota et al. Advanced Pharmacology
Cao et al. The Whole is Greater than the Sum of the Parts, Combination Use as CABENUVA in Treating HIV: Meta-Analysis from Clinical Datasets

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110729